Sudeep Pharma Peer Comparison

NSE: SUDEEPPHRM | BSE: 544619

₹1,164.90

₹21.50 (1.88%)

As on 25-Sep-2026IST

Market cap

₹13,199 Cr

Revenue (TTM)

₹676 Cr

P/E Ratio

72.3

P/B Ratio

14.3

Div. Yield

0.1 %

Edit

	Sudeep Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	13,199	36,902	28,103	16,761	15,213
Revenue (₹ Cr)	676	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	183.60	1,018.97	497.77	603.02	270.18
Net Margin (%)	26.06	10.47	20.72	22.63	23.29
RoE (%)	22.72	21.30	28.49	19.61	14.45
Price to Earnings	72.27	36.49	56.46	27.79	55.25
Price-To-Book	14.29	7.05	13.90	4.81	7.34

Income Statement (₹ Cr)

	Sudeep Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	675.61	9,683.45	2,371.81	2,590.40	1,108.39
Total Income	704.48	9,730.84	2,402.61	2,664.23	1,159.90
Total Expenditure	442.67	7,739.53	1,608.91	1,753.71	720.01
EBITDA	232.94	1,943.92	762.90	836.69	388.38
Depreciation	15.56	425.10	98.11	78.88	74.78
EBIT	217.38	1,518.82	664.79	757.81	313.60
Interest	7.96	148.45	26.33	5.43	0.26
Other Income	28.87	47.39	30.80	73.83	51.50
Exceptional Items	0.00	-27.85	0.00	-25.66	-3.28
Profit before Tax	238.30	1,389.91	669.26	800.55	361.56
Provision for Tax	54.69	370.94	171.48	197.53	91.39
Profit after Tax	183.60	1,018.97	497.77	603.02	270.18

	Sudeep Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	883.34	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	-0.97	-7.58	0.00	0.00	2.51
Non-Current Liabilities	74.82	723.57	345.47	142.73	50.51
Current Liabilities	201.96	3,912.24	710.20	508.04	169.08
Total Liabilities	1,174.38	9,514.48	2,930.14	4,157.10	2,231.79

	Sudeep Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	477.92	3,392.16	1,290.62	1,321.38	957.22
Current Assets	623.97	5,612.10	1,483.13	2,649.36	1,250.11
Total Assets	1,174.38	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	148.29	1,204.08	196.61	0.00	0.00
Net Current Assets	422.01	1,699.86	772.93	2,141.33	1,081.04
Contingent Liabilities	--	258.92	13.18	4.82	3.76

	Sudeep Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	69.55	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	-330.93	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	247.29	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	-14.09	93.92	-56.08	-69.08	11.28

	Sudeep Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	28.50	25.25	27.50	24.61	18.04
ROE (%)	22.72	21.30	28.49	19.61	14.45
ROA (%)	31.25	11.42	19.48	16.31	12.66
EBIT Margin (%)	32.18	15.68	28.03	29.25	28.29
Net Margin (%)	26.06	10.47	20.72	22.63	23.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Sudeep Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	23.56	18.36	78.33	7.93	-6.72
EBIT Growth (%)	12.00	30.43	303.07	19.88	-26.64
Net Profit Growth (%)	20.07	32.39	182.61	21.66	-24.38
EPS Growth (%)	50.65	36.68	277.72	25.42	-21.99
Book Value Growth (%)	79.97	11.36	22.95	18.43	11.27

	Sudeep Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	69.46	35.74	56.46	26.91	54.76
Price / Book Value	14.29	7.05	13.90	4.81	7.34
Dividend Yield (%)	0.13	0.19	0.16	0.37	0.52
EV/EBITDA	56.81	19.53	36.63	19.10	38.10
Market Cap (₹ Cr)	6,690.53	30,257.56	15,412.11	11,956.86	10,627.92

	Sudeep Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.04	0.05	0.09	0.00	0.00
Short term debt to equity ratio	0.12	0.16	--	--	--
Current Ratio	3.09	1.43	2.09	5.21	7.39
Quick Ratio	2.02	0.82	1.37	3.85	5.46
Interest Coverage	30.94	10.36	26.41	148.49	1,386.30

	Sudeep Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	33.68	26.46	22.82	41.42	41.52
Asset Turnover	1.15	1.09	0.93	0.70	0.52
Receivable days	115.16	88.68	77.32	144.58	169.86
Inventory Days	96.15	84.11	80.83	96.67	97.92
Payable days	106.08	176.65	125.94	135.45	159.68
Cash Conversion Cycle	105.23	-3.86	32.22	105.80	108.11

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.